Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

  • STATUS
    Recruiting
  • End date
    May 30, 2025
  • participants needed
    396
  • sponsor
    AstraZeneca
Updated on 22 June 2021
Investigator
AstraZeneca Clinical Study Information Center
Primary Contact
Research Site (0.0 mi away) Contact
+55 other location
fluticasone
albuterol

Summary

A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma

Description

This is a regional, multicentre, randomized, double-blind, placebo controlled, parallel group, phase 3 study designed to evaluate the efficacy and safety of 210 mg Q4W (SC) of tezepelumab in adults with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 396 subjects will be randomized regionally (China/non-China). Subjects will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks.

Details
Condition Asthma, Allergies & Asthma, Asthma (Pediatric), asthmatic, bronchial asthma
Treatment Placebo, Experimental: Tezepelumab
Clinical Study IdentifierNCT03927157
SponsorAstraZeneca
Last Modified on22 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age. 18-80
Documented physician-diagnosed asthma for at least 12 months
Subjects who have received a physician-prescribed asthma controller medication with medium or high dose ICS for at least 6 months
Documented treatment with a total daily dose of either medium or high dose ICS ( 500 g fluticasone propionate dry powder formulation equivalent total daily dose) for at least 3 months
At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months
Morning pre-BD FEV1 <80% predicted normal
Evidence of asthma as documented by either: Documented historical reversibility of FEV1 12% and 200 mL in the previous 12 months OR Post-BD (albuterol/salbutamol) reversibility of FEV1 12% and 200 mL during screening
Documented history of at least 2 asthma exacerbation events within 12 months, and at least one of the exacerbations should occur during the treatment of medium-to-high dose ICS
ACQ-6 score 1.5 at screening and on day of randomization

Exclusion Criteria

Pulmonary disease other than asthma
History of cancer
History of a clinically significant infection
Current smokers or subjects with smoking history 10 pack-yrs
History of chronic alcohol or drug abuse within 12 months
Hepatitis B, C or HIV
Pregnant or breastfeeding
History of anaphylaxis following any biologic therapy
Subject randomized in the current study or previous tezepelumab studies
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note